200 related articles for article (PubMed ID: 35408914)
21. Dual-action ambroxol in treatment of chronic pain in Gaucher Disease.
Pawlinski L; Krawczyk M; Fiema M; Tobor E; Kiec-Wilk B
Eur J Pain; 2020 May; 24(5):992-996. PubMed ID: 31994807
[TBL] [Abstract][Full Text] [Related]
22. Conformationally-locked N-glycosides: exploiting long-range non-glycone interactions in the design of pharmacological chaperones for Gaucher disease.
Castilla J; Rísquez R; Higaki K; Nanba E; Ohno K; Suzuki Y; Díaz Y; Ortiz Mellet C; García Fernández JM; Castillón S
Eur J Med Chem; 2015 Jan; 90():258-66. PubMed ID: 25461326
[TBL] [Abstract][Full Text] [Related]
23. Fluorinated Chaperone-β-Cyclodextrin Formulations for β-Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease.
García-Moreno MI; de la Mata M; Sánchez-Fernández EM; Benito JM; Díaz-Quintana A; Fustero S; Nanba E; Higaki K; Sánchez-Alcázar JA; García Fernández JM; Ortiz Mellet C
J Med Chem; 2017 Mar; 60(5):1829-1842. PubMed ID: 28171725
[TBL] [Abstract][Full Text] [Related]
24. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.
Lieberman RL; D'aquino JA; Ringe D; Petsko GA
Biochemistry; 2009 Jun; 48(22):4816-27. PubMed ID: 19374450
[TBL] [Abstract][Full Text] [Related]
25. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D
Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808
[TBL] [Abstract][Full Text] [Related]
26. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
[TBL] [Abstract][Full Text] [Related]
27. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis.
Shanmuganathan M; Britz-McKibbin P
Anal Bioanal Chem; 2011 Mar; 399(8):2843-53. PubMed ID: 21286689
[TBL] [Abstract][Full Text] [Related]
28. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.
Orwig SD; Tan YL; Grimster NP; Yu Z; Powers ET; Kelly JW; Lieberman RL
Biochemistry; 2011 Dec; 50(49):10647-57. PubMed ID: 22047104
[TBL] [Abstract][Full Text] [Related]
29. Enzyme enhancement activity of N-octyl-beta-valienamine on beta-glucosidase mutants associated with Gaucher disease.
Lei K; Ninomiya H; Suzuki M; Inoue T; Sawa M; Iida M; Ida H; Eto Y; Ogawa S; Ohno K; Suzuki Y
Biochim Biophys Acta; 2007 May; 1772(5):587-96. PubMed ID: 17363227
[TBL] [Abstract][Full Text] [Related]
30. Scaffolds for Sustained Release of Ambroxol Hydrochloride, a Pharmacological Chaperone That Increases the Activity of Misfolded β-Glucocerebrosidase.
Enshaei H; Molina BG; Del Valle LJ; Estrany F; Arnan C; Puiggalí J; Saperas N; Alemán C
Macromol Biosci; 2019 Aug; 19(8):e1900130. PubMed ID: 31222941
[TBL] [Abstract][Full Text] [Related]
31. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Zimran A; Altarescu G; Elstein D
Blood Cells Mol Dis; 2013 Feb; 50(2):134-7. PubMed ID: 23085429
[TBL] [Abstract][Full Text] [Related]
32. N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease.
Lin H; Sugimoto Y; Ohsaki Y; Ninomiya H; Oka A; Taniguchi M; Ida H; Eto Y; Ogawa S; Matsuzaki Y; Sawa M; Inoue T; Higaki K; Nanba E; Ohno K; Suzuki Y
Biochim Biophys Acta; 2004 Aug; 1689(3):219-28. PubMed ID: 15276648
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.
Babajani G; Tropak MB; Mahuran DJ; Kermode AR
Mol Genet Metab; 2012 Jul; 106(3):323-9. PubMed ID: 22592100
[TBL] [Abstract][Full Text] [Related]
34. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
[TBL] [Abstract][Full Text] [Related]
35. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
Suzuki Y
Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
[TBL] [Abstract][Full Text] [Related]
36. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
Huang J; Xu J; Tian L; Zhong L
Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
[TBL] [Abstract][Full Text] [Related]
37.
Ciana G; Dardis A; Pavan E; Da Riol RM; Biasizzo J; Ferino D; Zanatta M; Boni A; Antonini L; Crichiutti G; Bembi B
Mol Genet Metab Rep; 2020 Dec; 25():100678. PubMed ID: 33294373
[TBL] [Abstract][Full Text] [Related]
38. Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases.
Bouscary A; Quessada C; René F; Spedding M; Henriques A; Ngo S; Loeffler JP
Eur J Pharmacol; 2020 Oct; 884():173446. PubMed ID: 32739173
[TBL] [Abstract][Full Text] [Related]
39. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease.
Sanders A; Hemmelgarn H; Melrose HL; Hein L; Fuller M; Clarke LA
Blood Cells Mol Dis; 2013 Aug; 51(2):109-15. PubMed ID: 23642305
[TBL] [Abstract][Full Text] [Related]
40. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease.
Brumshtein B; Greenblatt HM; Butters TD; Shaaltiel Y; Aviezer D; Silman I; Futerman AH; Sussman JL
J Biol Chem; 2007 Sep; 282(39):29052-29058. PubMed ID: 17666401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
